Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma.

Wang W, Qiu J, Liu Z, Zeng Y, Fan J, Liu Y, Guo Y.

J Surg Oncol. 2013 Jun;107(7):758-61. doi: 10.1002/jso.23317. Epub 2013 Apr 23.

PMID:
23609182
2.

The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.

Wang P, Lin SL, Zhang LH, Li Z, Liu Q, Gao JX, Liu DM, Bo JJ, Huang YR.

Eur J Surg Oncol. 2014 Mar;40(3):255-9. doi: 10.1016/j.ejso.2013.12.018. Epub 2014 Jan 2.

PMID:
24429027
3.

E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.

Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP.

J Urol. 2001 May;165(5):1473-9.

PMID:
11342899
4.

Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.

Su JS, Arima K, Hasegawa M, Franco OE, Umeda Y, Yanagawa M, Sugimura Y, Kawamura J.

Int J Urol. 2004 Feb;11(2):74-82.

5.

Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.

Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C.

Urology. 2004 Jun;63(6):1079-83.

PMID:
15183954
6.

Predictive value of maspin and Ki-67 expression in transurethral resection specimens in patients with T1 bladder cancer.

Acikalin D, Oner U, Can C, Acikalin MF, Colak E.

Tumori. 2012 May-Jun;98(3):344-50. doi: 10.1700/1125.12403.

PMID:
22825520
7.

Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.

Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.

Urology. 2004 Oct;64(4):839-44.

PMID:
15491744
8.

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.

J Surg Oncol. 2012 Mar 15;105(4):425-30. doi: 10.1002/jso.22087. Epub 2011 Aug 30.

PMID:
22311819
9.
10.

Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.

Gou Y, Ding W, Xu K, Wang H, Chen Z, Tan J, Xia G, Ding Q.

Int Urol Nephrol. 2015 Feb;47(2):289-93. doi: 10.1007/s11255-014-0874-z. Epub 2014 Nov 12.

PMID:
25388353
11.

Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.

May M, Helke C, Nitzke T, Vogler H, Hoschke B.

Urol Int. 2004;72(2):103-11.

PMID:
14963349
12.

Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE.

J Natl Cancer Inst. 1993 Jan 6;85(1):53-9.

PMID:
7677935
13.

[Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence].

Janane A, Hajji F, Ismail TO, Elondo JC, Ghadouane M, Ameur A, Abbar M, Bouzidi A.

Actas Urol Esp. 2011 Apr;35(4):189-94. doi: 10.1016/j.acuro.2010.11.017. Epub 2011 Mar 17. Spanish.

PMID:
21419519
14.

Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.

Hemal AK, Khaitan A, Dinda AK, Gupta NP, Seth A, Dogra PN, Nabi G.

Urol Int. 2003;70(1):42-6.

PMID:
12566814
15.

T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.

De Berardinis E, Busetto GM, Antonini G, Giovannone R, Gentile V.

Int Urol Nephrol. 2011 Dec;43(4):1047-57. doi: 10.1007/s11255-011-9941-x. Epub 2011 Mar 29.

PMID:
21442469
16.

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.

Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF.

Urology. 2007 Sep;70(3):482-6.

PMID:
17905101
17.

Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.

Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F.

Cancer. 2004 Jun 1;100(11):2367-75.

18.

HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).

Bongiovanni L, Arena V, Vecchio FM, Racioppi M, Bassi P, Pierconti F.

Arch Ital Urol Androl. 2013 Jun 24;85(2):73-7. doi: 10.4081/aiua.2013.2.73.

19.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk